The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia
Abstract
Purpose: There has been little survival improvement in older patients with acute myeloid leukemia (AML) in the last two decades. Improving induction treatment may improve the rate and quality of remission and consequently survival. In our previous trial, in younger patients, we showed improved survival for the majority of patients when adding gemtuzumab ozogamicin (GO) to induction chemotherapy. Patients and Methods: Untreated patients with AML or high-risk myelodysplastic syndrome (median age, 67 years; range, 51 to 84 years) were randomly assigned to receive induction chemotherapy with either daunorubicin/ara-C or daunorubicin/clofarabine, with (n = 559) or without (n = 556) GO 3 mg/m 2 on day 1 of course one of therapy. The primary end point was overall survival (OS). Results: The overall response rate was 69% (complete remission [CR], 60%; CR with incomplete recovery [CRi], 9%), with no difference between GO (70%) and no GO (68%) arms. There was no difference in 30- or 60-day mortality and no major increase in toxicity with GO. With median follow-up of 30 months (range, 5.5 to 54.6 months), 3-year cumulative incidence of relapse was significantly lower with GO (68% v 76%; hazard ratio [HR], 0.78; 95% CI, 0.66 to 0.93; P = .007), and 3-year survival was significantly better (25% v 20%; HR, 0.87; 95% CI, 0.76 to 1.00; P = .05). The benefit was apparent across subgroups. There was no interaction with other treatment interventions. A meta-analysis of 2,228 patients in two United Kingdom National Cancer Research Institute trials showed significant improvements in relapse (HR, 0.82; 95% CI, 0.72 to 0.93; P = .002) and OS (HR, 0.88; 95% CI, 0.79 to 0.98; P = .02). Conclusion: Adding GO (3 mg/m 2) to induction chemotherapy reduces relapse risk and improves survival with little increase in toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
Self-citationCheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Creutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Age and acute myeloid leukemia
Appelbaum, F. R., Gundacker, H., Head, D. R., Slovak, M. L., Willman, C. L., Godwin, J. E., Anderson, J. E., & Petersdorf, S. H. (2006) · Blood · doi:10.1182/blood-2005-09-3724 · Cited by 1,350
Anthracycline Dose Intensification in Acute Myeloid Leukemia
Fernandez, H. F., Sun, Z., Yao, X., Litzow, M. R., Luger, S. M., Paietta, E. M., Racevskis, J., Dewald, G. W., Ketterling, R. P., Bennett, J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904544 · Cited by 919
Sievers, E. L., Larson, R. A., Stadtmauer, E. A., Estey, E., Löwenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J. M., Sherman, M. L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3244 · Cited by 899
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
Löwenberg, B., Ossenkoppele, G. J., van Putten, W., Schouten, H. C., Graux, C., Ferrant, A., Sonneveld, P., Maertens, J., Jongen-Lavrencic, M., von Lilienfeld-Toal, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901409 · Cited by 828
Therapeutic Advances in Acute Myeloid Leukemia
Burnett, A., Wetzler, M., & Löwenberg, B. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1820 · Cited by 787
Self-citationBurnett, A. K., Hills, R. K., Milligan, D., Kjeldsen, L., Kell, J., Russell, N. H., Yin, J. A. L., Hunter, A., Goldstone, A. H., & Wheatley, K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.4310 · Cited by 657
Self-citationLarson, R. A., Sievers, E. L., Stadtmauer, E. A., Löwenberg, B., Estey, E. H., Dombret, H., Theobald, M., Voliotis, D., Bennett, J. M., Richie, M., et al. (2005) · Cancer · doi:10.1002/cncr.21326 · Cited by 460
A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells
Griffin, J. D., Linch, D., Sabbath, K., Larcom, P., & Schlossman, S. F. (1984) · Leukemia Research · doi:10.1016/0145-2126(84)90001-8 · Cited by 403
Taussig, D. C. (2005) · Blood · doi:10.1182/blood-2005-03-1072 · Cited by 370
Giles, F. J., Kantarjian, H. M., Kornblau, S. M., Thomas, D. A., Garcia-Manero, G., Waddelow, T. A., David, C. L., Phan, A. T., Colburn, D. E., Rashid, A., et al. (2001) · Cancer · doi:10.1002/1097-0142(20010715)92:2<406::aid-cncr1336>3.0.co;2-u · Cited by 283
Feldman, E. J., Brandwein, J., Stone, R., Kalaycio, M., Moore, J., O'Connor, J., Wedel, N., Roboz, G. J., Miller, C., Chopra, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.133 · Cited by 249
Wheatley, K., Brookes, C. L., Howman, A. J., Goldstone, A. H., Milligan, D. W., Prentice, A. G., Moorman, A. V., Burnett, A. K., & on behalf of the United Kingdom National Cancer Research Institute Haematological Oncology Clinical Studies Group and Acute Myeloid Leukaemia Subgroup (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07663.x · Cited by 236
Self-citationHamann, P. R., Hinman, L. M., Beyer, C. F., Lindh, D., Upeslacis, J., Flowers, D. A., & Bernstein, I. (2002) · Bioconjugate Chemistry · doi:10.1021/bc0100206 · Cited by 230
Petersdorf, S., Kopecky, K., Stuart, R. K., Larson, R. A., Nevill, T. J., Stenke, L., Slovak, M. L., Tallman, M. S., Willman, C. L., Erba, H., et al. (2009) · Blood · doi:10.1182/blood.v114.22.790.790 · Cited by 184
Caron, P., Jurcic, J., Scott, A., Finn, R., Divgi, C., Graham, M., Jureidini, I., Sgouros, G., Tyson, D., & Old, L. (1994) · Blood · doi:10.1182/blood.v83.7.1760.1760 · Cited by 181
Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation
Nencioni, A., von Schwarzenberg, K., Brauer, K. M., Schmidt, S. M., Ballestrero, A., Grünebach, F., & Brossart, P. (2006) · Blood · doi:10.1182/blood-2005-08-3494 · Cited by 135
Lane, S., & Gilliland, D. G. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.12.001 · Cited by 98
Assessment of minimal residual disease in acute myeloid leukemia
Grimwade, D. J., Vyas, P., & Freeman, S. D. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833ed831 · Cited by 81
Self-citation
Cited by
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., et al. (2022) · Blood · doi:10.1182/blood.2022016867 · Cited by 3,279
Self-citationAntibody–Drug Conjugates: A Comprehensive Review
Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U., & Zhang, J. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0582 · Cited by 787
Acute myeloid leukemia: current progress and future directions
Kantarjian, H., Kadia, T., DiNardo, C., Daver, N., Borthakur, G., Jabbour, E., Garcia-Manero, G., Konopleva, M., & Ravandi, F. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00425-3 · Cited by 776
Hills, R. K., Castaigne, S., Appelbaum, F. R., Delaunay, J., Petersdorf, S., Othus, M., Estey, E. H., Dombret, H., Chevret, S., Ifrah, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70281-5 · Cited by 721
Self-citation
Metadata
- Authors
- Burnett, A. K., Russell, N. H., Hills, R. K., Kell, J., Freeman, S., Kjeldsen, L., Hunter, A. E., Yin, J., Craddock, C. F., Dufva, I. H., Wheatley, K., & Milligan, D.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-11-10
- Volume
- 30
- Issue
- 32
- Pages
- 3924-3931
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2153310476
- Cited by
- 409
- References
- 21
- FWCI
- 31.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.